Vigonvita (Lianyungang) Pharmaceutical Co., Ltd is located in Lianyungang National Development Zone, China Pharmaceutical Port, covering an area of 33 acres. It has an API and formulation production system that meets domestic and international GMP standards and EHS (environmental, health, and safety) requirements. The first phase of construction has been largely completed, and GMP certification has been obtained. The facility is scheduled to commence production in June 2024, with an annual designed capacity of 100 million capsules and 600 million tablets. It is capable of handling the production of active pharmaceutical ingredients (APIs) and formulations for both innovative and generic drugs at various stages.
